Antisense and nuclear medicine

Journal of Nuclear Medicine

Volumn 40, Issue 4, 1999, Pages 693-703

  Hnatowich, D J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antisense; Deoxyribonucleic acid; Imaging; Radiolabeling

Indexed keywords

COMPLEMENTARY DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; COLON CROHN DISEASE; DRUG DNA BINDING; DRUG USE; HUMAN; INFLAMMATION; ISOTOPE LABELING; PRIORITY JOURNAL; VIRUS INFECTION;

ANIMALS; DNA, ANTISENSE; HUMANS; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS;

EID: 0032906375     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Ts'o POP, Miller PS, Geene JJ. Nucleic acid analogs with targeted delivery as chemotherapeutic agents. In: Cheng YC, Goz B, Minkoff M, eds. Development of Target-Oriented Anticancer Drugs. New York, NY: Raven Press; 1983:183.
2. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:285-288.
3. Roush W. Antisense aims for a renaissance. Science. 1997;276:1192-1193.
4. Anonymous. Antisense '97:a roundtable on the state of the industry. Nat Biotech. 1997;15:519-524.
5. Rawls RL. Optimistic about antisense. Chem Eng News. 1997;75:35-39.
6. Temsamani J, Agrawal S. Antisense oligonucleotides as antiviral agents. Adv Antiviral Drug Des. 1996:21-39.
7. Ma L, Calvo F. Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol. 1996;10:97-115.
8. Putnam DA. Antisense strategies and therapeutic applications. Am J Health-Syst Pharm. 1996;53:151-159.
9. Mack A. Companies create new antisense drugs as clinical trials progress. The Scientist. 1996;10:1-9.
10. Akhtar A, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharm Sci. 1997;18:12-18.
11. Narayanan R, Akhtar S. Antisense Therapy. Curr Opin Oncol. 1996;8:509-515.
12. Rossi GC, Pasternak GW. Establishing the molecular biology of opioid behavior through antisense approaches. In: Weiss B, ed. Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents. New York, NY: CRC Press;1997:115-148.
13. Diasio RB, Zhang R. Pharmacology of therapeutic oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997;7:239-243.
14. Uhlmann E, Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chem Rev. 1990;90:543-584.
15. Goodchild J. Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconj Chem. 1990;1:165-187.
16. Miller PS. A brief guide to nucleic acid chemistry. Bioconj Chem. 1990;1:87-191.
17. Bischofberger N, Shea RG. Oligonucleotide-based therapeutics. In: Propst CL, Perun TJ, eds. Nucleic Acid Targeted Drug Design. New York, NY: Marcel Dekker, Inc.; 1992:579-612.
18. Hnatowich DJ. Radiolabeled oligonucleotides in nuclear medicine. In: Maisey MN, Britton KE, Collier BD, eds. Clinical Nuclear Medicine. New York, NY: Chapman and Hall; 1998:637-644.
19. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Radiolabeled antisense oligodeoxynucleotides: in vitro and in vivo applications. J Clin Immunol. 1993;16:276-289.
20. Kairemo KJ., Tenhunen M, Jekunen AP. Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetics and tissue distribution data. Antisense Nucleic Acid Drug Dev. 1996;6:215-220.
21. 125I incorporated into a triplex-forming oligonucleotide correlates with the geometry of the triplex. Nucleic Acids Res. 1997;25:883-887.
22. Crooke ST. Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv Pharm. 1997;40:1-47.
23. Mirabelli CK, Crooke ST. Antisense oligonucleotides in the context of modern molecular drug discovery and development. In: Crooke ST, Lebleu B, eds. Antisense Research and Applications. Boca Raton. FL: CRC Press: 1993:7-35.
24. Piwnica-Worms D. Making sense out of anti-sense: Challenges of imaging gene translation with radiolabeled oligonucleotides. J Nucl Med. 1994;35:1064-1066.
25. Helene C. The anti-gene strategey: control of gene expression by triplex-forming oligonucleotides. Anticancer Drug Des. 1991;6:569-784.
26. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transciption factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 1995;92:5855-5859.
27. Durland RH, Kessler DJ, Gunnell S, Duvic M, Pettitt BM, Hogan ME. Binding of triple helix forming oligonucleotides to sites in gene promoters. Biochem. 1991;30:9246-9255.
28. Ho PTC, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol. 1997; 24:187-202.
29. Dean NM, Griffey RH. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997;7:229-233.
30. Branch AD. A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatology. 1996;24:1517-1529.
31. Minshull J, Hunt T. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res. 1986;14:6433-6451.
32. Lima WF, Monia BP, Ecker DJ, Freier SM. Implications of RNA stucture on antisense olignucleotide hybridization kinetics. Biochem. 1992;31:12055-12061.
33. Baskerville S, Ellington AD. Describing the elephant. Curr Biol. 1995;5:120-123.
34. Wagner RW. Gene inhibition using antisense oligonucleotides. Nature. 1994;372: 333-335.
35. Oberstrass J, Nellen W. Regulating genes with antisense RNA. In: Weiss B, ed. Antisense Oligondeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents. New York, NY: CRC Press; 1997:171-195.
36. Cook PD. Medicinal chemistry of antisense oligonucleotides: future opportunities. Anticancer Drug Des. 1991;6:585-607.
37. Crooke ST. Commentary: Regulatory issues affecting oligonucleotides. Antisense Res Dev. 1993;3:301.
38. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev. 1993;3:53-66.
39. Wittung P, Kajanus J, Edwards K, Nielsen P, Norden B, Malmstrom BG. Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett. 1995;365:27-29.
40. Pardrige WM, Boado RJ, Kang Y-S. Vector-mediated delivery of a polyamine ("peptide") nucleic analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA. 1995;92:5592-5596.
41. Stein CA. Controversies in the cellular pharmacology of oligondeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1997;7:207-209.
42. Loke SL, Stein CA, Zhang XH, et al. Characterization off oligonucleotide transport into living cells. Proc Natl Acad Sci USA. 1989;86:3474-3478.
43. Gao W-Y, Storm C, Egan W, Cheng Y-C. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol. 1993;43:45-50.
44. Yakubov L, Deeva EA, Zarylova VF, et al. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA. 1989;86: 6454-6458.
45. Phillips MI, Gyurko R. Antisense oligodeoxynucleotides targeted to the antiotensin system as a novel strategy to treat hypertension. In: Weiss B, ed. Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents. New York, NY: CRC Press; 1997:131-148.
46. Lewis JG, Lin K-Y, Kothavale A, et al. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotidies and plasmin DNA. Proc Natl Acad Sci USA. 1996;93:3176-3181.
47. Agrawal S, Akhtar S. Advances in antisense efficacy and delivery. Tibtech. 1995;13:197-199.
48. Gewirtz AM, Stein CA, Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA. 1996;93:3161-3163.
49. Wagner E, Zenke M, Cotten M, Beug H, Birnstiel ML. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Cancer Soc USA. 1990; 87:3410-3414.
50. Leonetti JP, Machy P, Degols GB, Leserman L. Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA. 1990;87:2448-2451.
51. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivitives of poly(ethylene glycol) show prolonged circulation half-times in vivo. Biochim Biophys Acta. 1991;1066:29-36.
52. Friedmann T. Overcoming the obstacles to gene therapy. Scientific American. 1997;276:96-101.
53. Parasrampuria DA, Hunt CA. Therapeutic delivery issues in gene therapy, Part 1:Vectors. Biopharm. 1998;11:38-45.
54. Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995;28:7-16.
55. Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2′-modified oligonucleotides containing 2′deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268:14514-14522.
56. Rouhi M. Antisense drug design shifts gear. Chem Eng News. 1996;74:38-39.
57. Guinosso CJ, Hoke G, Frier S, et al. Synthesis and biophysical and biological evaluation of 2′-modified antisense oligonucleotides. Nucleosides Nucleotides. 1991;10:259-262.
58. Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides from nuclease resistance to biological efficacy in animals. Chimia. 1996;50:168-176.
59. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107-129.
60. Hnatowich DJ. Pharmacokinectic considerations in the development of oligomers as radiopharmaceuticals. Q J Nucl Med. 1997;41:91-100.
61. Woolf TM, Melton DA, Jennings CGB. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA. 1992;89:7305-7309.
62. Thein SL, Wallace RP. The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders. In: Davis KE, ed. Human Genetic Diseases: A Practical Approach. Oxford, UK: IRL Press; 1986:3-50.
63. Branch A. D. A good antisense molecule is hard to find. Tibtech. 1998;23:45-50.
64. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acid Res. 1998;16:3209-3221.
65. Gao W-Y, Han F-S, Storm C, Egan W, Cheng Y-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol Pharmacol. 1992;41:223-229.
66. Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994;269: 26801-26805.
67. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994;4:67-69.
68. Stein CA. Does antisense exist? Nat Med. 1995;1:1119-1121.
69. 99mTc. J Nucl Med. 1995;36:2306-2314.
70. Agrawal S. Antisense oligonucleotides: towards clinical trials. Tibtech. 1996;14: 376-387.
71. Urbain JLC, Shore SK, Vekemans MC, et al. Scintigraphic imaging of oncogenes with antisense probes: does it make sense? Eur J Nucl Med. 1995;22:499-504.
72. Dewanjee MK, Ghafouripour AK, Kapodvanjwala M, et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994;35:1054-1063.
73. Henry SP, Monteith D, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 1997;12:395-408.
74. Crooke RM. Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides. In: Crooke ST, Lebleu B, eds. Antisense Research and Applications. Boca Raton, FL: CRC Press, 1993:427-449.
75. 14C labeled afovirsen sodium in patients with genital warts. Clin Pharm Ther. 1994;56:641-646.
76. Wallace TL, Bazemore SA, Kornbrust DJ, Cossum PA. 1. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J Pharmacol Exp Therap. 1996;278:1306-1312.
77. Fjalling M, Andersson P, Forsell-Aronsson E, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe-Octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519-1521.
78. Kassis AI, Adelstein SJ, Haydock C, Sastry KSR, McElvany KD, Welch MJ. Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res. 1982;90:362-373.
79. McLean JR, Blakey DH, Douglas GR, Bayley J. The Auger electron dosimetry of indium-111 in mammalian cells in vitro. Radiat Res. 1989;119:205-218.
80. Shapiro J. Radiation protection. A Guide for Scientists and Physicians. 2nd ed. Cambridge, MA: Harvard University Press; 1981.
81. Wickstrom E. Antisense c-myc inhibition of lymphoma growth. Antisense Nucleic Acid Drug Dev. 1997;7:225-228.
82. Mehta HB, Popovich BK, Dillmann WH. Ischemia induces changes in the level of mRNAs coding for stress protein 71 and creatin kinase M. Circ Res. 1988;63:512-517.
83. Taggart DP, Bakkenist CJ, Biddolph SC, Graham AK, McGee JO. Induction of myocardial heat shock protein 70 during cardiac surgery. J Pathol. 1997;182:362-366.
84. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotech. 1997;15:537-541.
85. Commerford SL. Iodination of nucleic acids in vitro. Biochem. 1971;10:1993-1999.
86. 125I-labeled oligonucleotides from tributylstannylbenzamide conjugates. Bioconj Chem. 1997;8:238-243.
87. Dougan H, Hobbs JB, Weitz JI, Lyster DM. Synthesis and radioiodination of a stannyl oligodeoxyribonucleotide. Nucleic Acids Res. 1997;25:2897-2901.
88. 3 for technetium-99m labeling of DNA. Nucl Med Biol. 1997;24:425-432.
89. 111In-labeled antisense oligodeoxynucletide probes by high-pressure liquid chromatography. Biotechniques. 1994;16:844-850.
90. Mardirossian G, Lei K, Rusckowski M, et al. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med. 1997;38:907-913.
91. Dewanjee MK. Radiolabeled antisense probes: diagnosis and therapy. Diagn Oncol. 1993;3:189-208.
92. Bennett CF. Antisense oligonucleotides: is the glass half full or half empty? Biochem Pharm. 1998;55:9-19.
93. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Vol. 2. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Lab Press; 1989:11.23-11.28.
94. Lu X, Fischman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J Nucl Med. 1994;35:269-275.
95. Cammilleri S, Sangrajrang S, Perdereau B, et al. Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection. Eur J Nucl Med. 1996;23:448-452.
96. Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB. Regulation of gene expression by small molecules. Nature. 1997;387:202-205.